Literature DB >> 19128278

Direct renin inhibition--commonly asked questions.

Domenic A Sica1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19128278      PMCID： PMC8673093          DOI： 10.1111/j.1751-7176.2008.00039.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  29 in total

1.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

2.  Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema.

Authors:  Daniel Amalio Anzaldua; Paul G Schmitz
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

3.  Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.

Authors:  Yagiz Uresin; Addison A Taylor; Charles Kilo; Diethelm Tschöpe; Massimo Santonastaso; Ghionul Ibram; Hui Fang; Andrew Satlin
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2007-12       Impact factor: 1.636

4.  Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.

Authors:  Sujata Vaidyanathan; Gian Camenisch; Helmut Schuetz; Christine Reynolds; Ching-Ming Yeh; Marie-Noelle Bizot; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  J Clin Pharmacol       Date:  2008-09-10       Impact factor: 3.126

Review 5.  Kinetics of angiotensin-converting enzyme inhibitors in renal failure.

Authors:  D A Sica
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

6.  Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.

Authors:  Michel Azizi; Joël Ménard; Alvine Bissery; Than-Tam Guyene; Alessandra Bura-Rivière
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-08       Impact factor: 8.237

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

Review 8.  Aliskiren: a review of its use in the management of hypertension.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

10.  Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.

Authors:  George L Bakris; David Hg Smith; Thomas D Giles; William B White; Giora Davidai; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-10       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.